 Regulus Therapeutics Inc NASDAQ: RGLS announced the presentation of additional data from the first cohort from Phase 1b trial of RGLS4326 for autosomal dominant polycystic kidney disease ADPKD, as well as new preclinical data. The data were shared at the PKD Connect Conference 2021. 